DERM · Journey Medical Corp
$6.72
+0.07 (+1.05%)
At close · Aug 14
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“However, as a result of recurring and historical losses, substantial doubt exists about the Company's ability to continue as a going concern for a period of at least twelve months from the date of issuance of these financial statements.”View the 10-Q filed Aug 12, 2026
Market Cap
$189.67M
Shares
28.22M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Claude Maraoui | President and Chief Executive Officer | $1,665,876 |
| Ramsey Alloush | Chief Operating Officer, Corporate Secretary and General Counsel | $1,194,192 |
| Joseph Benesch | Chief Financial Officer | $823,673 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Claude Maraoui | Chief Executive Officer | $2,597,684 |
| Ramsey Alloush | Chief Operating Officer, Corporate Secretary and General Counsel | $1,573,350 |
| Joseph Benesch | Chief Financial Officer | $1,175,688 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Claude Maraoui | Chief Executive Officer | $934,450 |
| Joseph Benesch | Chief Financial Officer | $409,035 |
| Ernie De Paolantonio | Former Chief Financial Officer | $32,962 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Claude Maraoui | Chief Executive Officer | $1,873,300 |
| Ernie De Paolantonio | Former Chief Financial Officer | $1,458,700 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Claude Maraoui | Chief Executive Officer | $1,569,648 |
| Nirav Jhaveri | — | $527,841 |
| Ernie De Paolantonio | Chief Financial Officer | $150,368 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Former Chief | Executive Officer | $501,423 |
Executive changes
Key facts
CIK
1867066
CUSIP
48115J109
13F (30d)
71 filings
69 filers
Visit website
Investor relations